Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 16,859 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Human Immunodeficiency Virus (HIV), Hepatitis C (HCV)
Interventions: Video Format with Captions, Video Format without Captions, Health Educator; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
Interventions: Solriamfetol 150 mg Oral Tablet; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Acute Lung Injury, Adult Respiratory Distress Syndrome
Interventions: Low-tidal-volume ventilation, Airway Pressure Release Ventilation (APRV); Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
Interventions: Fludarabine, Fractionated total body irradiation, Busulfan, Cyclophosphamide, Single dose total body irradiation, Melphalan, Granulocyte-colony stimulating factor, Stem cell transplant, Azacitidine; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Dexmedetomidine, Placebos; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 89 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more

Conditions: Ichthyosis, Netherton Syndrome
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 1 Year to 60 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York

Conditions: HIV Infections
Interventions: VRC-HIVDNA016-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 44 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kawasaki Disease
Interventions: Anakinra; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 1 Month to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Bloom Syndrome
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 2 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: ketamine/amitriptyline NP-H cream, placebo; Drug · Other
Lead sponsor: Gary Morrow; Other
Eligibility: 18 Years to 120 Years
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 17
States / cities: Honolulu, Hawaii • Chicago, Illinois • Decatur, Illinois + 14 more

Conditions: Patellofemoral Pain Syndrome
Interventions: Home Exercise Program (HEP), NMES, TENS; Other · Device
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 45 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fort Campbell North, Kentucky

Conditions: Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
Interventions: Groundskeeper; Device
Lead sponsor: CogCubed, Corp; Industry
Eligibility: 5 Years to 12 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Polycystic Ovary Syndrome
Interventions: DCI, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions: inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Hour to 1 Week
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Kidney Transplant
Interventions: Berinert, Placebo for Berinert; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 1 more

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 16
States / cities: Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
Interventions: olanzapine and melatonin; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2024
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: HIV Infections
Interventions: Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Sherman Oaks, California + 6 more

Conditions: Dry Eye
Interventions: DE-101 ophthalmic suspension, DE-101 ophthalmic suspension vehicle; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 10
States / cities: Inglewood, California • Torrance, California • Bloomfield, Connecticut + 7 more

Conditions: Acute Respiratory Failure, Encephalopathy, ARDS, Sepsis, Critical Illness
Interventions: Exersides; Device
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Burlington, Vermont

Conditions: Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
Interventions: anakinra; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: atazanavir/ritonavir, lopinavir/ritonavir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Interventions: Emapalumab; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 6 Months to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Untreated Adult Acute Myeloid Leukemia
Interventions: midostaurin, azacitidine, bone marrow aspiration, mutation analysis, Pharmacokinetic study; Drug · Other
Lead sponsor: Brenda Cooper, MD; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio • Morgantown, West Virginia

Search by objective public record fields.

Persuasive Health Communication Intervention for HIV/HCV

Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

Acute Lung Injury Ventilator Evaluation (ALIVE)

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

Defining the Skin and Blood Biomarkers of Ichthyosis

Candidate HIV Vaccine

Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

Biological Significance of the Bloom's Syndrome Protein

Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients

Trial of Self-managed Approaches for Patellofemoral Pain Syndrome in Active Duty

GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs

Oral Administration of DCI to Women With PCOS

Inhaled Nitric Oxide by Oxygen Hood in Neonates

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

aHUS Observational Long Term Follow-Up

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

Metabolic Effects of Switching Kaletra to Boosted Reyataz

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia